TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 23708466

Group type: EXPERIMENTAL
Intervention: Lisdexamfetamine dimesylate (LDX) 30, 50 or 70 mg
Number of subjects: 317

Group type: EXPERIMENTAL
Intervention: Osmotic-release oral system methylphenidate (OROS-MPH)
Number of subjects: 317

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 317
Study: 23362296

Group type: EXPERIMENTAL
Intervention: FTC/TDF
Number of subjects: 311

Group type: COMPARATOR
Intervention: 3TC/ABC
Number of subjects: 311
Study: 20844049

Group type: EXPERIMENTAL
Intervention: Chloroquine (CQ) therapy
Number of subjects: 0
Study: 18164043

Group type: EXPERIMENTAL
Intervention: Cognitive restraint (measured using the Three-Factor Eating Questionnaire)
Number of subjects: 24
Study: 15671215

Group type: EXPERIMENTAL
Intervention: Oral L-arginine (12 g/d for 3 wk)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 12509647

Group type: EXPERIMENTAL
Intervention: Zincum gluconicum nasal gel (33 mmol/l), administered four times daily until symptoms resolved, for a maximum of 10 days.
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo nasal gel, administered four times daily until symptoms resolved, for a maximum of 10 days.
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Zincum gluconicum nasal gel
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo nasal gel
Number of subjects: 80
Study: 10933617

Group type: EXPERIMENTAL
Intervention: Zidovudine plus lamivudine
Number of subjects: 92

Group type: COMPARATOR
Intervention: Stavudine
Number of subjects: 92
Study: 9016421

Group type: EXPERIMENTAL
Intervention: L-thyroxine replacement therapy
Number of subjects: 37

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37
Study: 1642912

Group type: EXPERIMENTAL
Intervention: Total i.v. anaesthesia (TIVA: propofol and alfentanil)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Inhalation technique (propofol and alfentanil followed by nitrous oxide and isoflurane)
Number of subjects: 50
Study: 6443759

Group type: EXPERIMENTAL
Intervention: Piroxicam (40 mg for the first 2 days, then 20 mg daily)
Number of subjects: 1282

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1282

Group type: EXPERIMENTAL
Intervention: Piroxicam
Number of subjects: 1282

Group type: COMPARATOR
Intervention: Piroxicam and Placebo
Number of subjects: 1282
Study: 30266267

Group type: EXPERIMENTAL
Intervention: Education intervention
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 80
Study: 29878617

Group type: EXPERIMENTAL
Intervention: Platelet-rich plasma (PRP) injections (n=45)
Number of subjects: 89

Group type: COMPARATOR
Intervention: Hyaluronic acid (HA) injections (n=44)
Number of subjects: 89
Study: 25252255

Group type: EXPERIMENTAL
Intervention: Sealed in-office bleaching technique using 35% hydrogen peroxide gel for a single 45-min application.
Number of subjects: 20

Group type: COMPARATOR
Intervention: Conventional in-office bleaching technique using 35% hydrogen peroxide gel for a single 45-min application.
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Sealed in-office bleaching technique.
Number of subjects: 20

Group type: COMPARATOR
Intervention: Conventional in-office bleaching technique.
Number of subjects: 20
Study: 23249399

Group type: EXPERIMENTAL
Intervention: Group psychoeducational program (12 weekly sessions of 1.5 hours each led by two nurses)
Number of subjects: 246

Group type: COMPARATOR
Intervention: Usual care (Control group)
Number of subjects: 246
Study: 20675669

Group type: EXPERIMENTAL
Intervention: Exercise training group (ETG)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Inactive control group (ICG)
Number of subjects: 40
Study: 18394266

Group type: EXPERIMENTAL
Intervention: epoetin zeta
Number of subjects: 609

Group type: COMPARATOR
Intervention: epoetin alpha
Number of subjects: 609
Study: 16110722

Group type: EXPERIMENTAL
Intervention: Bootstrap method for cost-effectiveness analysis
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Resampling individuals and clusters
Number of subjects: 0
Study: 14583178

Group type: EXPERIMENTAL
Intervention: Aldose reductase inhibitor (ARI); administration details not specified
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (nondiabetic patients and control rats)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Diabetic rats
Number of subjects: 0
Study: 9987171

Group type: EXPERIMENTAL
Intervention: Hepagene vaccine (5, 10, 20, and 40 micrograms/ml)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hepagene vaccine (5 micrograms/ml)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hepagene vaccine (10 micrograms/ml or more)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Repeated 'S' containing vaccines
Number of subjects: 0
Study: 8341891

Group type: EXPERIMENTAL
Intervention: High dose methamphetamine (40-60 mg)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Low dose methamphetamine (20 mg)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control group (5 or 10 mg methamphetamine)
Number of subjects: 16
Study: 3521691

Group type: EXPERIMENTAL
Intervention: Captopril 50 mg orally with naloxone intravenously
Number of subjects: 6

Group type: COMPARATOR
Intervention: Captopril 50 mg orally with 0.9% saline vehicle (placebo) intravenously
Number of subjects: 6
Study: 29472258

Group type: EXPERIMENTAL
Intervention: Creating Learning Environments for Compassionate Care (CLECC) intervention
Number of subjects: 627

Group type: COMPARATOR
Intervention: Control (No educational activity)
Number of subjects: 627

Group type: COMPARATOR
Intervention: Nursing empathy (measured by Jefferson Scale of Empathy)
Number of subjects: 627
Study: 27605230

Group type: EXPERIMENTAL
Intervention: Celecoxib (COX-2 inhibitor) for 4 weeks postoperatively
Number of subjects: 23

Group type: COMPARATOR
Intervention: Control group (no COX-2 inhibitor)
Number of subjects: 23
Study: 25612162

Group type: EXPERIMENTAL
Intervention: Periconal blockade with ultrasound guidance (n = 69)
Number of subjects: 129

Group type: COMPARATOR
Intervention: Periconal blockade without ultrasound guidance (n = 60)
Number of subjects: 129
Study: 23359230

Group type: EXPERIMENTAL
Intervention: Oral ibuprofen
Number of subjects: 99

Group type: COMPARATOR
Intervention: Intravenous ibuprofen
Number of subjects: 99
Study: 22045673

Group type: EXPERIMENTAL
Intervention: PEG-IFNα-2a 180 μg/week for 48 weeks
Number of subjects: 544

Group type: COMPARATOR
Intervention: PEG-IFNα-2a 90 μg/week for 24 weeks
Number of subjects: 544

Group type: COMPARATOR
Intervention: PEG-IFNα-2a 90 μg/week for 48 weeks
Number of subjects: 544

Group type: COMPARATOR
Intervention: PEG-IFNα-2a 180 μg/week for 24 weeks
Number of subjects: 544
Study: 20087260

Group type: EXPERIMENTAL
Intervention: Sequential treatment with 4 cycles of carboplatine and etoposide followed by conformal radiotherapy (RT)
Number of subjects: 85

Group type: COMPARATOR
Intervention: Concurrent treatment with cisplatine and etoposide and conformal RT followed by two cycles of consolidation chemotherapy of carboplatine and etoposide
Number of subjects: 85
Study: 16339287

Group type: EXPERIMENTAL
Intervention: Reciprocating syringe
Number of subjects: 100

Group type: COMPARATOR
Intervention: Conventional syringe
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Both syringes
Number of subjects: 100
Study: 15318539

Group type: EXPERIMENTAL
Intervention: Profenid (ketoprofen)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Veral (diclofenac)
Number of subjects: 60
Study: 10960939

Group type: EXPERIMENTAL
Intervention: Gemcitabine in combination with cisplatin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Non-cisplatin-based gemcitabine doublet combinations
Number of subjects: 0
Study: 9665617

Group type: EXPERIMENTAL
Intervention: Activation of the right hippocampal formation during word priming
Number of subjects: 13
Study: 8034872

Group type: EXPERIMENTAL
Intervention: Complete ST segment resolution (> or = 70%)
Number of subjects: 1817

Group type: EXPERIMENTAL
Intervention: Partial ST segment resolution (< 70% to 30%)
Number of subjects: 1817

Group type: EXPERIMENTAL
Intervention: No ST segment resolution (< 30% to > 0%)
Number of subjects: 1817
Study: 2920504

Group type: EXPERIMENTAL
Intervention: Olestra
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Triglyceride oil
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Water
Number of subjects: 0
Study: 31937362

Group type: EXPERIMENTAL
Intervention: Intervention group (kindergarten-based intervention to increase vegetable intake)
Number of subjects: 633
Study: 30488617

Group type: EXPERIMENTAL
Intervention: Fluvoxamine (100 mg twice a day) plus Amantadine (100 mg daily)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Fluvoxamine (100 mg twice a day) plus Placebo
Number of subjects: 100
Study: 29798120

Group type: EXPERIMENTAL
Intervention: Saccharomyces boulardii combined with levocetirizine hydrochloride
Number of subjects: 90

Group type: COMPARATOR
Intervention: Levocetirizine hydrochloride (control group)
Number of subjects: 90
Study: 26151090

Group type: EXPERIMENTAL
Intervention: Roflumilast treatment
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 27
Study: 23324437

Group type: EXPERIMENTAL
Intervention: nateglinide
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: acarbose
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control (BMI-matched normoglycemic subjects)
Number of subjects: 40
Study: 21454915

Group type: EXPERIMENTAL
Intervention: Mint drink 3 times a day for 1 week
Number of subjects: 24

Group type: COMPARATOR
Intervention: Off-menthol (avoiding menthol-containing products and mint drink) for 1 week
Number of subjects: 24
Study: 18444813

Group type: EXPERIMENTAL
Intervention: Artesunate plus amodiaquine
Number of subjects: 26
Study: 16927225

Group type: EXPERIMENTAL
Intervention: Internal limiting membrane (ILM) peeling
Number of subjects: 10

Group type: COMPARATOR
Intervention: No ILM peeling (Control)
Number of subjects: 10
Study: 14535877

Group type: EXPERIMENTAL
Intervention: Lansoprazole 30 mg daily for 8 weeks
Number of subjects: 43

Group type: COMPARATOR
Intervention: No treatment (control group)
Number of subjects: 43
Study: 11098486

Group type: EXPERIMENTAL
Intervention: UFT plus leucovorin
Number of subjects: 1530

Group type: COMPARATOR
Intervention: 5-FU plus leucovorin
Number of subjects: 1530
Study: 9408065

Group type: EXPERIMENTAL
Intervention: Losartan (12.5 mg once daily)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Picotamide (300 mg b.i.d.)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 8229143

Group type: EXPERIMENTAL
Intervention: Audiotape of consultation
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: Audiotape describing cancer in general terms
Number of subjects: 142

Group type: COMPARATOR
Intervention: No tape
Number of subjects: 142
Study: 3807243

Group type: EXPERIMENTAL
Intervention: Fornix-based flap
Number of subjects: 61

Group type: COMPARATOR
Intervention: Limbus-based flap
Number of subjects: 61
Study: 29764706

Group type: EXPERIMENTAL
Intervention: Rivaroxaban monotherapy
Number of subjects: 2200

Group type: COMPARATOR
Intervention: Rivaroxaban plus an antiplatelet drug (aspirin, clopidogrel, or prasugrel)
Number of subjects: 2200
Study: 27740618

Group type: EXPERIMENTAL
Intervention: Binaural beat music (BB)
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: Plain music intervention (MI)
Number of subjects: 141

Group type: COMPARATOR
Intervention: Control group (ear phones with no music)
Number of subjects: 141
Study: 25007667

Group type: EXPERIMENTAL
Intervention: Nasopharyngeal airway (NPA)
Number of subjects: 216

Group type: COMPARATOR
Intervention: Control group (no NPA)
Number of subjects: 216
Study: 22554994

Group type: EXPERIMENTAL
Intervention: Brushing with 200g force after acid and enzyme treatment
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Brushing with 300g force after acid and enzyme treatment
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Brushing with 400g force after acid and enzyme treatment
Number of subjects: 4

Group type: COMPARATOR
Intervention: Control group (no brushing)
Number of subjects: 4
Study: 20715524

Group type: EXPERIMENTAL
Intervention: Remifentanil
Number of subjects: 18

Group type: COMPARATOR
Intervention: Fentanyl
Number of subjects: 18
Study: 18036846

Group type: EXPERIMENTAL
Intervention: Interscalene block (ISB)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Subacromial bursa block (SBB)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (no block)
Number of subjects: 60
Study: 16194498

Group type: EXPERIMENTAL
Intervention: Monthly home visits with intercalated phone calls from trained nursing staff
Number of subjects: 300
Study: 11792880

Group type: EXPERIMENTAL
Intervention: (99m)Tc-1.2B6-Fab
Number of subjects: 26

Group type: COMPARATOR
Intervention: (99m)Tc-oxidronate (99m)Tc-HDP
Number of subjects: 26

Group type: COMPARATOR
Intervention: (99m)Tc-HDP
Number of subjects: 26
Study: 10640164

Group type: EXPERIMENTAL
Intervention: MPA/E2C (Lunelle Monthly Contraceptive Injection)
Number of subjects: 1103

Group type: COMPARATOR
Intervention: NET/EE (Ortho-Novum 7/7/7)
Number of subjects: 1103

Group type: EXPERIMENTAL
Intervention: MPA/E2C
Number of subjects: 1103

Group type: COMPARATOR
Intervention: NET/EE
Number of subjects: 1103

Group type: EXPERIMENTAL
Intervention: MPA/E2C and NET/EE
Number of subjects: 1103
Study: 7856526

Group type: EXPERIMENTAL
Intervention: gemfibrozil (1,200 mg/day)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: simvastatin (20 mg/day)
Number of subjects: 45
Study: 1950173

Group type: EXPERIMENTAL
Intervention: Health education program 'Gesund leben macht Spass' (Healthy living is fun), a 7-week program.
Number of subjects: 413

Group type: EXPERIMENTAL
Intervention: Health education program 'Gesund leben macht Spass' (Healthy living is fun)
Number of subjects: 413

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 413
Study: 7000229

Group type: EXPERIMENTAL
Intervention: Suction drainage for 24 hours in complicated hernias
Number of subjects: 301

Group type: EXPERIMENTAL
Intervention: Suction drainage for 24 hours in simple hernias
Number of subjects: 301

Group type: COMPARATOR
Intervention: Control group (no suction drainage) in complicated hernias
Number of subjects: 301

Group type: COMPARATOR
Intervention: Control group (no suction drainage) in simple hernias
Number of subjects: 301
Study: 30929965

Group type: EXPERIMENTAL
Intervention: Lacrycon® eye drops
Number of subjects: 0
Study: 28583879

Group type: EXPERIMENTAL
Intervention: Calcium supplementation during pregnancy (F-Ca)
Number of subjects: 447

Group type: COMPARATOR
Intervention: Placebo during pregnancy (F-P)
Number of subjects: 447

Group type: EXPERIMENTAL
Intervention: Calcium supplementation during pregnancy (M-Ca)
Number of subjects: 447

Group type: COMPARATOR
Intervention: Placebo during pregnancy (M-P)
Number of subjects: 447
Study: 25963404

Group type: EXPERIMENTAL
Intervention: Flaxseed (FS) 40 g daily for 4 weeks
Number of subjects: 15
Study: 23889312

Group type: EXPERIMENTAL
Intervention: Children's Cancer Group (CCG) modified Berlin‐Frankfurt‐Muenster (BFM) acute lymphoblastic leukaemia (ALL) regimen with intensified intrathecal (IT) methotrexate (MTX) (Arm A1)
Number of subjects: 254

Group type: EXPERIMENTAL
Intervention: Children's Cancer Group (CCG) modified Berlin‐Frankfurt‐Muenster (BFM) acute lymphoblastic leukaemia (ALL) regimen with intensified intrathecal (IT) methotrexate (MTX) and intensification (Arm A2)
Number of subjects: 254

Group type: EXPERIMENTAL
Intervention: Adapted non‐Hodgkin lymphoma/BFM-95 therapy with high dose MTX in interim maintenance but no IT‐MTX in maintenance (Arm B1)
Number of subjects: 254

Group type: EXPERIMENTAL
Intervention: Adapted non‐Hodgkin lymphoma/BFM-95 therapy with high dose MTX in interim maintenance but no IT‐MTX in maintenance and intensification (Arm B2)
Number of subjects: 254

Group type: EXPERIMENTAL
Intervention: CNS positive patients (n = 12)
Number of subjects: 254

Group type: COMPARATOR
Intervention: CNS‐negative patients
Number of subjects: 254
Study: 21078700

Group type: EXPERIMENTAL
Intervention: diacutaneous fibrolysis
Number of subjects: 50

Group type: COMPARATOR
Intervention: placebo diacutaneous fibrolysis
Number of subjects: 50
Study: 19930870

Group type: EXPERIMENTAL
Intervention: Ankle-brachial index (ABI) screening
Number of subjects: 107
Study: 16501393

Group type: EXPERIMENTAL
Intervention: Inpatient/Residential treatment
Number of subjects: 274

Group type: EXPERIMENTAL
Intervention: Outpatient treatment
Number of subjects: 274

Group type: EXPERIMENTAL
Intervention: Any Treatment
Number of subjects: 274

Group type: EXPERIMENTAL
Intervention: Mutual Help Groups
Number of subjects: 274

Group type: EXPERIMENTAL
Intervention: Residential/Inpatient treatment
Number of subjects: 274
Study: 15255797

Group type: EXPERIMENTAL
Intervention: Rectal methadone (10 mg d(5)‐methadone‐HCl rectally)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Oral methadone (10 mg d(0)‐methadone orally)
Number of subjects: 7
Study: 11359593

Group type: EXPERIMENTAL
Intervention: 0.5 mg.kg‐1 ketamine
Number of subjects: 50

Group type: COMPARATOR
Intervention: 0.1 mg.kg‐1 morphine
Number of subjects: 50
Study: 9381265

Group type: EXPERIMENTAL
Intervention: IgA nebulization every 12 hours for 3 months
Number of subjects: 49

Group type: COMPARATOR
Intervention: Placebo nebulization every 12 hours for 3 months
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: IgA nebulization
Number of subjects: 49

Group type: COMPARATOR
Intervention: Placebo nebulization
Number of subjects: 49
Study: 8324915

Group type: EXPERIMENTAL
Intervention: Carbidopa 100 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Indomethacin 50 mg
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Saline infusion (0.9%)
Number of subjects: 12
Study: 3540308

Group type: EXPERIMENTAL
Intervention: Behavioral treatment program 1
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Behavioral treatment program 2
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Behavioral treatment program 3
Number of subjects: 75
Study: 31171725

Group type: EXPERIMENTAL
Intervention: Program with empathy exercise
Number of subjects: 370

Group type: COMPARATOR
Intervention: Program without empathy exercise
Number of subjects: 370
Study: 30208589

Group type: EXPERIMENTAL
Intervention: +LNS
Number of subjects: 20

Group type: COMPARATOR
Intervention: -LNS
Number of subjects: 20
Study: 27454264

Group type: COMPARATOR
Intervention: IV ibuprofen alone (800 mg at induction, 800 mg every 6 hours for up to 5 days)
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: IV ibuprofen (800 mg at induction, 800 mg every 6 hours for up to 5 days) + IV acetaminophen (1000 mg at closure, 800 mg + 1000 mg every 6 hours for up to 5 days)
Number of subjects: 78

Group type: COMPARATOR
Intervention: IV ibuprofen alone
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: IV ibuprofen + IV acetaminophen
Number of subjects: 78
Study: 23845320

Group type: EXPERIMENTAL
Intervention: Graduated compression stockings and subcutaneous injection of unfractionated heparin (unless contraindicated)
Number of subjects: 181

Group type: EXPERIMENTAL
Intervention: Duration of restraint
Number of subjects: 181

Group type: EXPERIMENTAL
Intervention: Excessive sedation
Number of subjects: 181

Group type: EXPERIMENTAL
Intervention: Antipsychotic dosage
Number of subjects: 181

Group type: EXPERIMENTAL
Intervention: Recent medical hospitalization
Number of subjects: 181
Study: 22407510

Group type: EXPERIMENTAL
Intervention: Pramipexole
Number of subjects: 63

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 63
Study: 19863495

Group type: EXPERIMENTAL
Intervention: 400 mL of milk fermented with Lactobacillus paracasei, ssp. paracasei F19, Lactobacillus acidophilus La5, and Bifidobacterium lactis Bb12 (Cultura; active)
Number of subjects: 74

Group type: COMPARATOR
Intervention: Acidified milk without probiotic bacteria (control)
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Active group
Number of subjects: 74
Study: 18829508

Group type: EXPERIMENTAL
Intervention: Docetaxel (60-75 mg/m² every 21 days) + Atrasentan (10 mg daily starting on day 3)
Number of subjects: 31
Study: 16485512

Group type: EXPERIMENTAL
Intervention: Angiotensin-converting enzyme (ACE) inhibitors
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Long-acting lipophilic ACE-inhibitors
Number of subjects: 0
Study: 12452468

Group type: EXPERIMENTAL
Intervention: 1 mg gemeprost vaginal pessary every 6 hours for 18 hours
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: 4 x 200 microg misoprostol tablets vaginally followed by 2 x 200 microg misoprostol tablets orally every 3 hours for 12 hours
Number of subjects: 100
Study: 10599982

Group type: EXPERIMENTAL
Intervention: Gemfibrozil 600 mg twice daily
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Combination therapy (fluvastatin 40 mg/d and gemfibrozil)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Normolipidemic controls
Number of subjects: 25
Study: 7547039

Group type: EXPERIMENTAL
Intervention: 1000 ml preload of crystalloid solution
Number of subjects: 60

Group type: COMPARATOR
Intervention: 200 ml preload of crystalloid solution
Number of subjects: 60
Study: 1743319

Group type: EXPERIMENTAL
Intervention: Oral micronized progesterone 300 mg
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Oral micronized progesterone 200 mg
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: All groups (300 mg, 200 mg, placebo)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Endogenous E2 and treatment P concentrations
Number of subjects: 60
Study: 7094642

Group type: EXPERIMENTAL
Intervention: Chlorpheniramine (8 mg)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Cimetidine (300 mg)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Lactose placebo
Number of subjects: 21
Study: 30740935

Group type: EXPERIMENTAL
Intervention: SMS-enhanced monitoring
Number of subjects: 166

Group type: COMPARATOR
Intervention: Routine care
Number of subjects: 166
Study: 30949875

Group type: EXPERIMENTAL
Intervention: Acute exercise (45 min bicycle test)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: 12 weeks of exercise intervention
Number of subjects: 26

Group type: COMPARATOR
Intervention: Baseline syndecan-4
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: mRNA levels in adipose tissue
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: mRNA levels in skeletal muscle
Number of subjects: 26
Study: 27931137

Group type: EXPERIMENTAL
Intervention: Olive oil-rich diet
Number of subjects: 17

Group type: COMPARATOR
Intervention: Usual diet
Number of subjects: 17
Study: 27488278

Group type: EXPERIMENTAL
Intervention: ASPIRE-Group
Number of subjects: 481

Group type: EXPERIMENTAL
Intervention: MOVE!
Number of subjects: 481

Group type: EXPERIMENTAL
Intervention: ASPIRE-Phone
Number of subjects: 481